This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Chemours (CC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Chemours (CC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $35.65 in the latest trading session, marking a +0.85% move from the prior day.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $32.44 in the latest trading session, marking a +0.43% move from the prior day.
Northern Technologies (NTIC) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Northern Technologies (NTIC) delivered earnings and revenue surprises of -33.33% and 4.84%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $32.32 in the latest trading session, marking a +0.19% move from the prior day.
Chemours (CC) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Chemours (CC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $32.18, moving +1.71% from the previous trading session.
Chemours (CC) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $30.55 in the latest trading session, marking a +0.03% move from the prior day.
Chemours (CC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $29.17, moving +1.14% from the previous trading session.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Chemours (CC) closed at $25.88, marking a +1.61% move from the previous day.
Chemours (CC) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Chemours (CC) Earnings Miss Estimates, Revenues Top in Q4
by Zacks Equity Research
Volumes and prices contributed favorably to Chemours' (CC) top-line growth in the fourth quarter. It sees adjusted earnings per share in the band of $4.07-$4.70 for 2022.
Chemours (CC) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Chemours' (CC) fourth-quarter performance is likely to reflect increasing customer adoption of Opteon refrigerants and the benefits from cost-cutting measures.
Linde (LIN) Gears Up to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Higher industrial gas sales are likely to have aided Linde's (LIN) Q4 earnings.
5 Chemical Stocks Likely to Outshine Q4 Earnings Estimates
by Anindya Barman
Strong end-market demand and benefits of self-help actions are likely to have been reflected in the Q4 performance of Huntsman (HUN), Chemours (CC), Westlake (WLK), ICL Group (ICL) and Green Plains (GPRE).
Chemours (CC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $32.71 in the latest trading session, marking a +0.74% move from the prior day.
This 1 Basic Materials Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $33.02 in the latest trading session, marking a +0.82% move from the prior day.
Why Chemours (CC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Chemours (CC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Chemours (CC) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
In the latest trading session, Chemours (CC) closed at $35.54, marking a -0.25% move from the previous day.
Royal Gold (RGLD) Issues Update for December-end Quarter
by Zacks Equity Research
Royal Gold (RGLD) sells 61,700 gold equivalent ounces (GEOs) during the December-end quarter.
Chemours (CC) Stock Up 32% in a Year: What's Driving It?
by Zacks Equity Research
Chemours (CC) benefits from strong end-market demand and its cost-reduction and pricing initiatives.
Chemours (CC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $35.57, moving +1.43% from the previous trading session.
Sandstorm Gold (SAND) Posts Preliminary Q4 Revenues, Up Y/Y
by Zacks Equity Research
Sandstorm Gold (SAND) reports higher GEOs sold year over year and preliminary Q4 revenues.